Resveratrol and chemoprevention

Cancer Letters

Volumn 284, Issue 1, 2009, Pages 1-6

  Goswami, Shyamal K ^a   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoprevention; Phytoestrogen; Phytonutrient; Resveratrol

Indexed keywords

BORTEZOMIB; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PICEATANNOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CANCER PREVENTION; COLON CANCER; DRUG ABSORPTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TISSUE LEVEL; ESTROGEN RESPONSIVE ELEMENT; HEART PROTECTION; HORMESIS; HUMAN; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; POLYGONUM CUSPIDATUM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA;

ANIMALIA; VACCINIUM; VITACEAE;

EID: 69049109766     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.041     Document Type: Review

References (93)

1. Flora S.D., Quaglia A., Bennicelli C., and Vercelli M. The epidemiological revolution of the 20th century. FASEB J. 19 (2005) 892-897
2. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol. 74 (2007) 533-544
3. Sporn M.B., Dunlop N.M., Newton D.L., and Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35 (1976) 1332-1338
4. Kwon K.H., Barve A., Yu S., Huang M.T., and Kong A.N.T. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin. 9 (2007) 1409-1421
5. De Flora S., and Ferguson L.R. Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 59 (2005) 8-15
6. Kumar N., Shibata D., Helm J., Coppola D., and Malafa M. Green tea polyphenols in the prevention of colon cancer. Front. Biosci. 12 (2007) 2309-2315
7. Johnson I.T. Phytochemicals and cancer. Proc. Nutr. Soc. 66 (2007) 207-215
8. Li Y., Fang H., and Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 7 (2007) 7663-7678
9. Liu R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 134 (2004) 3479S-3485S
10. Jeong W.S., Jun M., and Kong A.N. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox. Signal. 8 (2006) 99-106
11. Takaoka M.J. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University 7 (1999) 8-9
12. Nonomura S., Kanagawa H., and Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum Sieb. et Zucc.). Yakugaku Zasshi 83 (1963) 988-990
13. Richard J.L. Coronary risk factors The French paradox. Arch. Mal. Coeur. Vaiss. (1987) 17-21
14. Kopp P. Resveratrol a phytoestrogen found in red wine a possible explanation for the conundrum of the 'French paradox'. Eur. J. Endocrinol. 138 (1998) 619-620
15. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., and Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta 235 (1995) 207-219
16. Fitzpatrick D.F., Hirschfield S.L., and Coffey R.G. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 265 (1993) H774-778
17. Frankel E.N., Waterhouse A.L., and Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 341 (1993) 1103-1104
18. Asensi M., Medina I., Ortega A., Carretero J., Baño M.C., Obrador E., and Estrela J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33 (2002) 387-398
19. Walle T., Hsieh F., DeLegge M.H., Oatis Jr. J.E., and Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004) 1377-1382
20. Jannin B., Menzel M., Berlot J.P., Delmas D., Lançon A., and Latruffe N. Transport of resveratrol a cancer chemopreventive agent to cellular targets: plasmatic protein binding and cell uptake. Biochem. Pharmacol. 68 (2004) 113-118
21. Kaldas M.I., Walle U.K., and Walle T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 55 (2003) 307-312
22. Das D.K., and Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv. 6 (2006) 36-47
23. Rimando A.M., Cuendet M., Desmarchelier C., Mehta R.G., Pezzuto J.M., and Duke S.O. Cancer chemopreventive and antioxidant activities of pterostilbene a naturally occurring analogue of resveratrol. J. Agric. Food Chem. 50 (2002) 3453-3457
24. Wolter F., Clausnitzer A., Akoglu B., and Stein J. Piceatannol a natural analog of resveratrol inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr. 132 (2002) 298-302
25. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., Ruparelia K.C., Lamb J.H., Farmer P.B., Stanley L.A., and Burke M.D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 86 (2002) 774-778
26. Shin N.H., Ryu S.Y., Choi E.J., Kang S.H., Chang I.M., Min K.R., and Kim Y. Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase. Biochem. Biophys. Res. Commun. 243 (1998) 801-803
27. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol a natural product derived from grapes. Science 275 (1997) 218-220
28. Carbó N., Costelli P., Baccino F.M., López-Soriano F.J., and Argilés J.M. Resveratrol a natural product present in wine decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun. 254 (1999) 739-743
29. Wadsworth T.L., and Koop D.R. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol. 57 (1999) 941-949
30. Park J.W., Choi Y.J., Jang M.A., Lee Y.S., Jun D.Y., Suh S.I., Baek W.K., Suh M.H., Jin I.N., and Kwon T.K. Chemopreventive agent resveratrol a natural product derived from grapes reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett. 163 (2001) 43-49
31. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., and Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141 (2000) 3657-3667
32. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., and Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 27 (1999) 160-169
33. Miloso M., Bertelli A.A., Nicolini G., and Tredici G. Resveratrol-induced activation of the mitogen-activated protein kinases ERK1 and ERK2 in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 264 (1999) 141-144
34. Fontecave M., Lepoivre M., Elleingand E., Gerez C., and Guittet O. Resveratrol a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421 (1998) 277-279
35. Tsai S.H., Lin-Shiau S.Y., and Lin J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126 (1999) 673-680
36. Zheng J., and Ramirez V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 130 (2000) 1115-1123
37. Stewart J.R., Christman K.L., and O'Brian C.A. Effects of resveratrol on the autophos-phorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 60 (2000) 1355-1359
38. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B activator protein-1 and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164 (2000) 6509-6519
39. Casper R.F., Quesne M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., and Savouret J.F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 56 (1999) 784-790
40. Ciolino H.P., and Yeh G.C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 56 (1999) 760-767
41. Subbaramaiah K., Michaluart P., Chung W.J., Tanabe T., Telang N., and Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. NY Acad. Sci. 889 (1999) 214-223
42. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect. 16 (2003) 299-307
43. Srivastava R., Ratheesh A., Gude R.K., Rao K.V., Panda D., and Subrahmanyam G. Resveratrol inhibits type II phosphatidylinositol 4-kinase: a key component in pathways of phosphoinositide turn over. Biochem. Pharmacol. 70 (2005) 1048-1055
44. Borra M.T., Smith B.C., and Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280 (2005) 17187-17195
45. Regev-Shoshani G., Shoseyov O., and Kerem Z. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem. Biophys. Res. Commun. 323 (2004) 668-673
46. Vella F., Ferry G., Delagrange P., and Boutin J.A. NRH: quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 71 (2005) 1-12
47. Yang S., Irani K., Heffron S.E., Jurnak F., and Meyskens Jr F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 4 (2005) 1923-1935
48. Lin H.Y., Lansing L., Merillon J.M., Davis F.B., Tang H.Y., Shih A., Vitrac X., Krisa S., Keating T., Cao H.J., Bergh J., Quackenbush S., and Davis P.J. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 20 (2006) 1742-1744
49. Hambrock A., de Oliveira Franz C.B., Hiller S., Grenz A., Ackermann S., Schulze D.U., Drews G., and Osswald H. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J. Biol. Chem. 282 (2007) 3347-3356
50. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., and Nagarkatti P. Resveratrol (trans-3, 5, 4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 72 (2007) 1508-1521
51. Gledhill J.R., Montgomery M.G., Leslie A.G., and Walker J.E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. USA 104 (2007) 13632-13637
52. Cucciolla V., Borriello A., Oliva A., Galletti P., Zappia V., and Della Ragione F. Resveratrol: from basic science to the clinic. Cell Cycle 6 (2007) 2495-2510
53. Acconcia F., and Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 238 (2006) 1-14
54. Limer J.L., and Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 6 (2004) 119-127
55. Gehm B.D., McAndrews J.M., Chien P.Y., and Jameson J.L. Resveratrol a polyphenolic compound found in grapes and wine is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94 (1997) 14138-14143
56. Bhat K.P., Lantvit D., Christov K., Mehta R.G., Moon R.C., and Pezzuto J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61 (2001) 7456-7463
57. Turner R.T., Evans G.L., Zhang M., Maran A., and Sibonga J.D. Is resveratrol an estrogen agonist in growing rats. Endocrinology 140 (1999) 50-54
58. Lu R., and Serrero G. Resveratrol a natural product derived from grape exhibits antiestro-genic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 179 (1999) 297-304
59. Vyas S., Asmerom Y., and De León D.D. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology 146 (2005) 4224-4233
60. Choi H.K., Yang J.W., and Kang K.W. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett. 242 (2006) 198-206
61. Gougelet A., Mueller S.O., Korach K.S., and Renoir J.M. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. J. Steroid Biochem. Mol. Biol. 104 (2007) 110-122
62. Su J.L., Yang C.Y., Zhao M., Kuo M.L., and Yen M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J. Biol. Chem. 282 (2007) 19385-19398
63. Le Corre L., Fustier P., Chalabi N., Bignon Y.J., and Bernard-Gallon D. Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin. Chim. Acta 344 (2004) 15-21
64. Levenson A.S., Svoboda K.M., Pease K.M., Kaiser S.A., Chen B., Simons L.A., Jovanovic B.D., Dyck P.A., and Jordan V.C. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 62 (2002) 4419-4426
65. Sareen D., Darjatmoko S.R., Albert D.M., and Polans A.S. Mitochondria calcium and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol. 72 (2007) 1466-1475
66. Tang H.Y., Shih A., Cao H.J., Davis F.B., Davis P.J., and Lin H.Y. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5 (2006) 2034-2042
67. Wang Y., Lee K.W., Chan F.L., Chen S., and Leung L.K. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol. Sci. 92 (2006) 71-77
68. Watson C.S., Alyea R.A., Jeng Y.J., and Kochukov M.Y. Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol. Cell. Endocrinol. 274 (2007) 1-7
69. Chen J.Q., Yager J.D., and Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/ pathophysiological implications. Biochim. Biophys. Acta 1746 (2005) 1-17
70. Pietras R.J., Levin E.R., and Szego C.M. Estrogen receptors and cell signaling. Science 310 (2005) 51-53
71. Jacob J., Sebastian K.S., Devassy S., Priyadarsini L., Farook M.F., Shameem A., Mathew D., Sreeja S., and Thampan R.V. Membrane estrogen receptors: genomic actions and post transcriptional regulation. Mol. Cell. Endocrinol. 246 (2006) 34-41
72. Leonard S.S., Xia C., Jiang B.H., Stinefelt B., Klandorf H., Harris G.K., and Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 309 (2003) 1017-1026
73. Bianco N.R., Chaplin L.J., and Montano M.M. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 385 (2005) 279-287
74. Hebbar V., Shen G., Hu R., Kim B.R., Chen C., Korytko P.J., Crowell J.A., Levine B.S., and Kong A.N. Toxicogenomics of resveratrol in rat liver. Life Sci. 76 (2005) 2299-2314
75. Yang S., Irani K., Heffron S.E., Jurnak F., and Meyskens Jr. F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 4 (2005) 1923-1935
76. Azmi A.S., Bhat S.H., Hanif S., and Hadi S.M. Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. FEBS Lett. 580 (2006) 533-538
77. Wang S., Wang X., Yan J., Xie X., Fan F., Zhou X., Han L., and Chen J. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur. J. Pharmacol. 567 (2007) 26-35
78. Woo J.H., Lim J.H., Kim Y.H., Suh S.I., Min D.S., Chang J.S., Lee Y.H., Park J.W., and Kwon T.K. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23 (2004) 1845-1853
79. Rodrigue C.M., Porteu F., Navarro N., Bruyneel E., Bracke M., Romeo P.H., Gespach C., and Garel M.C. The cancer chemopreventive agent resveratrol induces tensin a cell-matrix adhesion protein with signaling and antitumor activities. Oncogene 5 (2005) 3274-3284
80. Kotha A., Sekharam M., Cilenti L., Siddiquee K., Khaled A., Zervos A.S., Carter B., Turkson J., and Jove R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5 (2006) 621-629
81. Alkhalaf M., and Jaffal S. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic. Biol. Med. 41 (2006) 318-325
82. Shimizu T., Nakazato T., Xian M.J., Sagawa M., Ikeda Y., and Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem. Pharmacol. 71 (2006) 742-750
83. Delmas D., Rébé C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., and Solary E. Redistribution of CD95 DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 (2004) 8979-8986
84. Heiss E.H., Schilder Y.D., and Dirsch V.M. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J. Biol. Chem. 282 (2007) 26759-26766
85. Bhardwaj A., Sethi G., Vadhan-Raj S., Bueso-Ramos C., Takada Y., Gaur U., Nair A.S., Shishodia S., and Aggarwal B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109 (2007) 2293-2302
86. Ulrich S., Loitsch S.M., Rau O., Knethen v.A., Brüne B., Schubert-Zsilavecz M., and Stein J.M. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res. 66 (2006) 7348-7354
87. Zhang Q., Tang X., Lu Q.Y., Zhang Z.F., Brown J., and Le A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 4 (2005) 1465-1474
88. Cao Z., Fang J., Xia C., Shi X., and Jiang B.H. trans-345'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 10 (2004) 5253-5263
89. Yang S., and Meyskens Jr. F.L. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol. Pharmacol. 67 (2005) 298-308
90. El-Mowafy A.M. Resveratrol activates membrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem. Biophys. Res. Commun. 291 (2002) 218-2124
91. Mattson M.P., Son T.G., and Camandola S. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Resp. 5 (2007) 174-186
92. Mattson M.P. Dietary factors hormesis and health. Age. Res. Rev. 7 (2008) 1-7
93. Jiang W.J. Sirtuins: novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun. 73 (2008) 341-344